Prodrugs pp 731-799 | Cite as

Prodrugs of Alcohols and Phenols

  • Sundeep S. Dhareshwar
  • Valentino J. Stella
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume V)


The rationale for the development of prodrugs is the delivery of a higher concentration of the pharmacologically active drugs into the systemic circulation and to its site of action. In general, poor systemic blood levels after drug administration are due to pharmaceutical or physiological causes, leading to either poor absorption or first-pass effects such as metabolism.


Parent Drug Amino Acid Ester Haloperidol Decanoate Clindamycin Phosphate Antibody Direct Enzyme Prodrug Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aarbakke J, Bakke OM, Milde EJ, and Davies DS. Disposition and Oxidative Metabolism of Phenylbutazone in Man. Eur J Clin Pharmacol 1977; 11:359–366PubMedGoogle Scholar
  2. Altomare C, Trapani G, Latrofa A, Serra M, Sanna E, Biggio, G, and Liso, G. Highly Water-soluble Derivatives of the Anesthetic Agent Propofol: In Vitro and In Vivo Evaluation of Cyclic Amino Acid Esters. Eur J Pharm Sci 2003; 20:17–26PubMedGoogle Scholar
  3. Ambrose PJ. Clinical Pharmacokinetics of Chloramphenicol and Chloramphenicol Succinate. Clin Pharmacokinet 1984; 9:222–238PubMedGoogle Scholar
  4. Amsberry KL, and Borchardt RT. Amine Prodrugs which Utilize Hydroxy Amide Lactonization. I. A Potential Redox-sensitive Amide Prodrug. Pharm Res 1991; 8:323–330PubMedGoogle Scholar
  5. Anderson, BD, and Taphouse V. Initial Rate Studies of Hydrolysis and Acyl Migration in Methylprednisolone 21-Hemisuccinate and 17-Hemisuccinate. J Pharm Sci 1981; 70:181–186PubMedGoogle Scholar
  6. Anderson, BD, Conradi RA, Spilman, CH, and Forbes AD. Strategies in the Design of Solution-stable, Water-soluble Prodrugs III: Influence of the Promoiety on the Bioconversion of 21-Esters of Corticosteroids. J Pharm Sci 1985a; 74:382–387PubMedGoogle Scholar
  7. Anderson, BD, Conradi RA, and Knuth KE. Strategies in the Design of Solutionstable, Water-soluble Prodrugs I: A Physical-Organic Approach To Pro-moiety Selection for 21-Esters of Corticosteroids. J Pharm Sci 1985b; 74:365–374PubMedGoogle Scholar
  8. Anderson, BD, Chu, WW, and Galinsky, RE. Reduction of First-pass Metabolism of Propranolol after Oral Administration of Ester Prodrugs. Int J Pharm 1988; 43:261–265Google Scholar
  9. Angenault, S, Thirot, S, Schmidt, F, Monneret, C, Pfeiffer, B, and Renard P. Cancer Chemotherapy: A SN-38 (7-ethyl-10-hydroxycamptothecin) Glucuronide Prodrug for Treatment by a PMT (Prodrug MonoTherapy) Strategy. Bioorg Med Chem Lett 2003; 13:947–950PubMedGoogle Scholar
  10. Ashida N, Ijichi K, Watanabe Y, and Machida H. Metabolism of 5′-Ether Prodrugs of 1-beta-D-Arabinofuranosyl-E-5-(2-bromovinyl)uracil in Rats. Biochem Pharmacol 1993; 46:2201–2207PubMedGoogle Scholar
  11. Bagshawe KD. Antibody Directed Enzymes Revive Anti-Cancer Prodrugs Concept. Br J Cancer 1987; 56:531–532PubMedGoogle Scholar
  12. Bagshawe KD. Towards Generating Cytotoxic Agents at Cancer Sites. Br J Cancer 1989; 60:275–281PubMedGoogle Scholar
  13. Barbas CF, Heine A, Zhong G, Hoffmann, T, Gramatikova S, Bjornestedt R, List B, Anderson J, Stura EA, Wilson IA, and Lerner RA. Immune versus Natural Selection: Antibody Aldolases with Enzymic Rates but Broader Scope. Science 1997; 278:2085–2092PubMedGoogle Scholar
  14. Barrett, AM, and Cullum VA. The Biological Properties of the Optical Isomers of Propranolol and Their Effects on Cardiac Arrhythmias. Br J Pharmacol 1968; 34:43–55Google Scholar
  15. Bauer K, Elger W, Schneider B, Krahl E, and Bauer R. Effect of Estradiol Sulfamate (ES-J995) on Affinity of Hemoglobin for Oxygen, Cardiovascular Function and Acid-Base Balance in Ovariectomized Rats. Exp Toxicol Pathology 2003; 55:301–307Google Scholar
  16. Beauchamp LM, Orr GF, De Miranda P, Burnette T, and Krenitsky TA. Amino Acid Ester Prodrugs of Acyclovir. Antiviral Chem Chemother 1992; 3:157–164Google Scholar
  17. Beijnen JH, Beijnen-Bandhoe AU, Dubbelman AC, Van Gijn R, and Underberg WJM. Chemical and Physical Stability of Etoposide and Teniposide in Commonly Used Infusion Fluids. J Parenter Sci Technol 1991; 45:108–112PubMedGoogle Scholar
  18. Bennett SN, McNeil MM, Bland LA, Arduino MJ, Villarino ME, and Perrotta DM. Postoperative Infections Traced to Contamination of an Intravenous Anesthetic, Propofol. N Engl J Med 1995; 333:147–154PubMedGoogle Scholar
  19. Bennett F, Girijavallabhan VM, Patel NM, Saksena AK, and Ganguly A. Tetrahydrofuran Antifungal Phosphate, Preparation Thereof, and Pharmaceutical Compositions. US Patent # 604325. (Mar 28). 2000Google Scholar
  20. Bennett F; Saksena AK, Lovey RG, Liu Y-T, Patel NM, Pinto P, Pike R, Jao E, Girijavallabhan VM, Ganguly AK, Loebenberg D, Wang H, Cacciapuoti A, Moss E, Menzel F, Hare RS, and Nomeir, A. Hydroxylated Analogues of the Orally Active Broad Spectrum Antifungal, Sch 51048 (1), and the Discovery of Posaconazole [Sch 56592; 2 or (S,S)-5]. Bioorg Med Chem Lett 2006; 16:186–190PubMedGoogle Scholar
  21. Bentley A, Butters M, Green SP, Learmonth WJ, MacRae JA, Morland MC, O’Connor G, and Skuse J. The Discovery and Process Development of a Commercial Route to a Water Soluble Prodrug, Fosfluconazole. Org Process Res Dev 2002; 6:109–112Google Scholar
  22. Beresford R, and Ward A. Haloperidol Decanoate. A Preliminary Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Use in Psychosis. Drugs 1987; 33:31–49PubMedGoogle Scholar
  23. Beutner KR. Valacyclovir: A Review of Its Antiviral Activity, Pharmacokinetic Properties, and Clinical Efficacy. Antiviral Res 1995; 28:281–290PubMedGoogle Scholar
  24. Blakey DC, Burke PJ, Davies DH, Dowell RL, East SJ, Eckersley KP, Fitton JE, McDaid J, Melton RG, Niculescu-Duvaz IA, Pinder PE, Sharma SK, Wright AF, and Springer CJ. ZD2767, An Improved System for Antibody-Directed Enzyme Prodrug Therapy that Results in Tumor Regressions in Colorectal Tumor Xenografts. Cancer Res 1996; 56:3287–3292PubMedGoogle Scholar
  25. Bodor N, El-Koussi A, Kano M, and Nakamura T. Improved Delivery through Biological Membranes. 26. Design, Synthesis, and Pharmacological Activity of a Novel Chemical Delivery System For β-Adrenergic Blocking Agents. J Med Chem 1988; 31:100–106PubMedGoogle Scholar
  26. Brent DA, Chandrasurin P, Ragouzeos A, Hurlbert BS, and Burke JT. Rearrangement of Chloramphenicol-3-monosuccinate. J Pharm Sci 1980; 69:906–908PubMedGoogle Scholar
  27. Brodie BB, and Axelrod J. Fate of Acetanilide in Man. J Pharmacol Exp Ther 1948; 94:29–38Google Scholar
  28. Brown, JM. SR 4233 (tirapazamine): A New Anticancer Drug Exploiting Hypoxia in Solid Tumors. Br J Cancer 1993; 67:1163–1170PubMedGoogle Scholar
  29. Bryson, HM, Fulton BR, and Faulds D. Propofol: An Update of its Use in Anesthesia and Conscious Sedation. Drugs 1995; 50:513–559PubMedGoogle Scholar
  30. Budman DR, Igwemezie LN, Kaul S, Behr J, Lichtman, S, Schulman P, Vinciguerra V, Allen SL, Kolitz J, and Hock K. Phase I Evaluation of a Water-soluble Etoposide Prodrug Etoposide Phosphate, Given as a 5-Minute iInfusion on Days 1, 3, and 5 in Patients with Solid Tumors. J Clin Oncol 1994; 12:1902–1909PubMedGoogle Scholar
  31. Bundgaard H, Larsen C, and Thorbek P. Prodrugs as Drug Delivery Systems. XXVI. Preparation and Enzymic Hydrolysis of Various Water-soluble Amino Acid Esters of Metronidazole. Int J Pharm 1984a; 18:67–77Google Scholar
  32. Bundgaard H, Larsen C, and Arnold E. Prodrugs as Drug Delivery Systems. XXVII. Chemical Stability and Bioavailability of a Water-soluble Prodrug of Metronidazole for Parenteral Administration. Int J Pharm 1984b; 18:79–87Google Scholar
  33. Bundgaard H, Buur A, Chang SC, and Lee VHL. Timolol Prodrugs: Synthesis, Stability and Lipophilicity of Various Alkyl, Cycloalkyl and Aromatic Esters of Timolol. Int J Pharm 1988a; 46:77–88Google Scholar
  34. Bundgaard H, Buur A, and Lee VHL. Timolol Prodrugs: Preparation and Hydrolysis Kinetics of N-Benzoyl Carbamate Esters of Timolol and Related Compounds. Acta Pharm Suec 1988b; 25:293–306PubMedGoogle Scholar
  35. Burke JT, Wargin WA, Sheretz RJ, Sanders KL, Blum MR, and Sarubbi FA. Pharmacokinetics of Intravenous Chloramphenicol Sodium Succinate in Adult Patients with Normal Renal and Hepatic Function. J Pharmacokinet Biopharm 1982; 10:601–614PubMedGoogle Scholar
  36. Caccia S, and Garattini S. Formation of Active Metabolites of Psychotropic Drugs. An Updated Review of their Significance. Clin Pharmacokinet 1990; 18:434–459PubMedGoogle Scholar
  37. Cambazard F. Clinical Efficacy of Velac, a New Tretinoin and Clindamycin Phosphate Gel in Acne Vulgaris. J Eur Acad Dermatalogy and Venereology 1998; 11Suppl 1:S20–S29Google Scholar
  38. Carl PL, Chakravarty PK, and Katzenellenbogen JA. A Novel Connector Linkage Applicable in Prodrug Design. J Med Chem 1981; 24:479–480PubMedGoogle Scholar
  39. Carty TJ, Marfat A, Moore PF, Falkner FC, Twomey TM, and Weissman A. Ampiroxicam, an Anti-inflammatory Agent which is a Prodrug of Piroxicam. Agents Actions 1993; 39:157–165PubMedGoogle Scholar
  40. Chapman TM, Plosker GL, and Perry CM. Fosamprenavir: A Review of its Use in the Management of Antiretroviral Therapy-Naive Patients with HIV Infection. Drugs 2004; 64:2101–2124PubMedGoogle Scholar
  41. Chien DS, Sasaki H, Bundgaard H, Buur A, and Lee VH. Role of Enzymatic Lability in the Corneal and Conjunctival Penetration of Timolol Ester Prodrugs in the Pigmented Rabbit. Pharm Res 1991; 8:728–733PubMedGoogle Scholar
  42. Cho MJ, Kurtz RR, Lewis C, Machkovech SM, and Houser DJ. Metronidazole Phosphate-A Water-soluble Prodrug for Parenteral Solutions of Metronidazole. J Pharm Sci 1982; 71:410–414PubMedGoogle Scholar
  43. Cho MJ, and Haynes LC. Serum-catalyzed Hydrolysis of Metronidazole Amino Acid Esters. J Pharm Sci 1985; 74:883–835PubMedGoogle Scholar
  44. Chong KT, Ruwart MJ, Hinshaw RR, Wilkinson KF, Rush BD, Yancey MF, Strohbach JW, and Thaisrivongs S. Peptidomimetic HIV Protease Inhibitors: Phosphate Prodrugs with Improved Biological Activities. J Med Chem 1993; 36:2575–2577PubMedGoogle Scholar
  45. Christenson I. Alkaline Hydrolysis of Some Carbamic Acid Esters. Acta Chem Scand 1964; 18:904–922Google Scholar
  46. Colla L, De Clercq E, Busson R, and Vanderhaeghe H. Synthesis and Antiviral Activity of Water-soluble Esters of Acyclovir [9-[(2-hydroxyethoxy)methyl]guanine]. J Med Chem 1983; 26:602–604PubMedGoogle Scholar
  47. Damen EWP, Nevalainen TJ, van den Bergh TJM, de Groot FMH, and Scheeren HW. Synthesis of Novel Paclitaxel Prodrugs Designed for Bioreductive Activation in Hypoxic Tumour Tissue. Bioorg Med Chem 2002; 10:71–77PubMedGoogle Scholar
  48. de Groot FMH, Damen EWP, and Scheeren HW. Anticancer Prodrugs for Application in Monotherapy: Targeting Hypoxia, Tumor-associated Enzymes, and Receptors. Curr Med Chem 2001a; 8:1093–1122PubMedGoogle Scholar
  49. de Groot FMH, Loos WJ, Koekkoek R, van Berkom LWA, Busscher GF, Seelen AE, Albrecht C, de Bruijn P, and Scheeren HW. Elongated Multiple Electronic Cascade and Cyclization Spacer Systems in Activatible Anticancer Prodrugs for Enhanced Drug Release. J Org Chem 2001b; 66:8815–8830PubMedGoogle Scholar
  50. de Groot FMH, vanBerkom LWA, and Scheeren HW. Synthesis and Biological Evaluation of 2′-Carbamate-linked and 2′-Carbonate-linked Prodrugs of Paclitaxel: Selective Activation by the Tumor-Associated Protease Plasmin. J Med Chem 2000; 43:3093–3102PubMedGoogle Scholar
  51. de Groot FMH, Busscher GF, Aben RWM, and Scheeren HW. Novel 20-Carbonate Linked Prodrugs of Camptothecin and 9-Aminocamptothecin Designed for Activation by Tumour-associated Plasmin. Bioorg Med Chem Lett 2002; 12:2371–2376PubMedGoogle Scholar
  52. de Groot FMH, Albrecht C, Koekkoek R, Beusker PH, and Scheeren HW. “Cascade-Release Dendrimers” Liberate All End Groups upon a Single Triggering Event in the Dendritic Core. Angew Chem Int Ed 2003; 42:4490–4494Google Scholar
  53. de Miranda P, Krasny HC, Page DA, and Elion GB. The Disposition of Acyclovir in Different Species. J Pharmacol Exp Ther 1981; 219:309–315PubMedGoogle Scholar
  54. de Vrueh RL, Smith PL, and Lee CP. Transport of L-valine-acyclovir via the Oligopeptide Transporter in the Human Intestinal Cell line, Caco-2. J Pharmacol Exp Ther 1998; 286:1166–1170PubMedGoogle Scholar
  55. DeHaan RM, Metzler CM, Schellenberg D, and Vandenbosch WD. Pharmacokinetic Studies of Clindamycin Phosphate. J Clin Pharmacol 1973; 13:190–209PubMedGoogle Scholar
  56. Denny WA, and Wilson WR. Tirapazamine: A Bioreductive Anticancer Drug that Exploits Tumour Hypoxia. Expert Opin Invest Drugs 2000; 9:2889–2901Google Scholar
  57. Derendorf H, Rohdewald P, Mollmann H, Rehder J, Barth J, and Neveling D. Pharmacokinetics of Prednisolone after High Doses of Prednisolone Hemisuccinate. Biopharm Drug Dispos 1985; 6:423–432PubMedGoogle Scholar
  58. Dillon MP, Cai H, and Maag H. Application of the “Trimethyl Lock” to Ganciclovir, A Pro-Prodrug with Increased Oral Bioavailability. Bioorg Med Chem Lett 1996; 6:1653–1656Google Scholar
  59. Doshi KJ, Islam Q, Gallo JM, Boudinot FD, Hsieh L, Qin Y, Schinazi RF, and Chu CK. Brain Targeting of Anti-HIV Nucleosides: Ether Prodrugs of 3′-Azido-2′,3′-dideoxyuridine (AZdU) and 3′-Azido-3′-deoxythymidine (AZT). Antiviral Chem Chemother 1993; 4:263–269Google Scholar
  60. Doursout MF, Joseph PM, Liang YY, Hartley CJ, and Chelly JE. Role of Propofol and its Solvent, Intralipid, in Nitric Oxide-induced Peripheral Vasodilatation in Dogs. Br J Anaesth 2002; 89:492–498PubMedGoogle Scholar
  61. El-Koussi AA, and Bodor N. Formation of Propranolol in the Iris-ciliary Body from its Propranolol Ketoxime Precursor-A Potential Antiglaucoma Drug. Int J Pharm 1989; 53:189–194Google Scholar
  62. Elger W, Schwarz S, Hedden A, Reddersen G, and Schneider B. Sulfamates of Various Estrogens are Prodrugs with Increased Systemic and Reduced Hepatic Estrogenicity at Oral Application. J Steroid Biochem Mol Biol 1995; 55:395–403PubMedGoogle Scholar
  63. Elger W, Barth A., Hedden, A., Reddersen G., Ritter P, Schneider B, Zuchner J, Krahl E, Muller K, Oettel M, and Schwarz, S. Estrogen Sulfamates: A New Approach to Oral Estrogen Therapy. Reprod Fertil Dev 2001; 13:297–305PubMedGoogle Scholar
  64. Ellis JM, Ross JW, and Coleman CI. Fosamprenavir: A Novel Protease Inhibitor and Prodrug of Amprenavir. Formulary 2004; 39:151–160Google Scholar
  65. Espinel-Ingroff A. Comparison of In Vitro Activities of the New Triazole SCH56592 and the Echinocandins MK-0991 (L-743,872) and LY303366 against Opportunistic Filamentous and Dimorphic Fungi and Yeasts. J Clin Microbiol 1998; 36:2950–2956PubMedGoogle Scholar
  66. Falkner FC, Twomey TM, Borgers AP, Garg D, Weidler D, Gerber N, and Browder IW. Disposition of Ampiroxicam, A Prodrug of Piroxicam, in Man. Xenobiotica 1990; 20:645–652PubMedGoogle Scholar
  67. Fechner J, Ihmsen H, Hatterscheid D, Schiessl C, Vornov JJ, Burak E, Schwilden H, and Schuettler J. Pharmacokinetics and Clinical Pharmacodynamics of the New Propofol Prodrug GPI 15715 in Volunteers. Anesthesiology 2003; 99:303–313PubMedGoogle Scholar
  68. Feigenbaum JJ, Bergmann F, Richmond SA, Mechoulam R, Nadler V, Kloog Y, and Sokolovsky M. Nonpsychotropic Cannabinoid acts as a Functional N-methyl-D-aspartate Receptor Blocker. Proc Natl Acad Sci 1989; 86:9584–9587PubMedGoogle Scholar
  69. Fields SZ, Igwemezie LN, Kaul S, Schacter LP, Schilder RJ, Litam PP, Himpler BS, McAleer C, Wright J, and Barbhaiya RH. Phase I study of Etoposide Phosphate (Etopophos) as a 30-Minute Infusion on days 1, 3, and 5. Clin Cancer Res 1995; 1:105–111PubMedGoogle Scholar
  70. Filer CW, Allen GD, Brown TA, Fowles SE, Hollis FJ, Mort EE, Prince WT, and Ramji JV. Metabolic and Pharmacokinetic Studies Following Oral Administration of 14 C-Famciclovir to Healthy Subjects. Xenobiotica 1994; 24:357–368PubMedGoogle Scholar
  71. Florent JC, Dong X, Gaudel G, Mitaku S, Monneret C, Gesson JP, Jacquesy J-C, Mondon M, Renoux B, Andrianomenjanahary S, Michel S, Koch M, Tillequin F, Gerken M, Czech J, Straub R, Bosslet K. Prodrugs of Anthracyclines for Use in Antibody-directed Enzyme Prodrug Therapy. J Med Chem 1998; 41:3572–3581PubMedGoogle Scholar
  72. Flower RJ. Drugs which Inhibit Prostaglandin Biosynthesis. Pharmacol Rev 1974; 26:33–67PubMedGoogle Scholar
  73. Francis RJ, Sharma SK, Springer C, Green AJ, Hope-Stone LD, Sena L, Martin J, Adamson KL, Robbins A, Gumbrell L, O’Malley D, Tsiompanou E, Shahbakhti H, Webley S, Hochhauser D, Hilson AJ, Blakey D, and Begent RHJ. A Phase I Trial of Antibody Directed Enzyme Prodrug Therapy (ADEPT) in Patients with Advanced Colorectal Carcinoma or Other CEA Producing Tumours. Br J Cancer 2002; 87:600–607PubMedGoogle Scholar
  74. Fredholt K, Mork N, and Begtrup M. Hemiesters of Aliphatic Dicarboxylic Acids as Cyclization-activated Prodrug Forms for Protecting Phenols against First-pass Metabolism. Int J Pharm 1995; 123:209–216Google Scholar
  75. Fugleholm AM, Ibsen TB, Laxmyr L, and Svendsen UG. Therapeutic Equivalence between Bambuterol, 10 mg Once Daily, and Terbutaline Controlled Release, 5 mg Twice Daily, in Mild to Moderate Asthma. Eur Respir J 1993; 6:1474–1478PubMedGoogle Scholar
  76. Furfine ES, Baker, CT, Hale MR, Reynolds DJ, Salisbury JA, Searle AD, Studenberg SD, Todd D, Tung RD, and Spaltenstein A. Preclinical Pharmacology and Pharmacokinetics of GW433908, A Water-soluble Prodrug of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir. Antimicrob Agents Chemother 2004; 48:791–798PubMedGoogle Scholar
  77. Galgiani JN, and Lewis ML. In Vitro Studies of Activities of the Antifungal Triazoles SCH56592 and Itraconazole against Candida Albicans, Cryptococcus Neoformans, and Other Pathogenic Yeasts. Antimicrob Agents Chemother 1997; 41:180–183PubMedGoogle Scholar
  78. Ganapathy ME, Huang W, Wang H, Ganapathy V, and Leibach FH. Valacyclovir: A Substrate for the Intestinal and Renal Peptide Transporters PEPT1 and PEPT2. Biochem Biophys Res Comm 1998; 246:470–475PubMedGoogle Scholar
  79. Gani D, and Wilkie J. Stereochemical, Mechanistic, and Structural Features of Enzyme-catalyzed Phosphate Monoester Hydrolyses. Chem Soc Rev 1995; 24:55–63Google Scholar
  80. Garattini E, Margolis J, Heimer E, Felix A, and Udenfriend S. Human Placental Alkaline Phosphatase in Liver and Intestine. Proc Natl Acad Sci 1985; 82:6080–6084PubMedGoogle Scholar
  81. Garceau Y, Davis I, and Hasegawa J. Plasma Propranolol Levels in Beagle Dogs after Administration of Propranolol Hemisuccinate Ester. J Pharm Sci 1978; 67:1360–1363PubMedGoogle Scholar
  82. Garrett ER. Prediction of Stability in Pharmaceutical Preparations X. Alkaline Hydrolysis of Hydrocortisone Hemisuccinate. J Pharm Sci 1962; 51:445–455PubMedGoogle Scholar
  83. Gaucher B, Rouquayrol M, Roche D, Greiner J, Aubertin A-M, and Vierling P. Prodrugs of HIV Protease Inhibitors-Saquinavir, Indinavir and Nelfinavir-Derived from Diglycerides or Amino Acids: Synthesis, Stability and Anti-HIV Activity. Org Biomol Chem 2004; 2:345–357PubMedGoogle Scholar
  84. George CF. Drug Metabolism by the Gastrointestinal Mucosa. Clin Pharmacokinet 1981; 6:259–274PubMedGoogle Scholar
  85. Girotra NN, Biftu T, Ponpipom MM, Acton JJ, Alberts AW, Bach TN, Ball RG, Bugianesi RL, Parsons WH, and Chabala JC. Development, Synthesis, and Biological Evaluation of (-)-trans-(2S,5S)-2-[3-[(2-Oxopropyl) sulfonyl]-4-npropoxy-5-(3-hydroxypropoxy)-phenyl]-5-(3,4,5-trimethoxyphenyl) Tetrahydrofuran, A Potent Orally Active Platelet-activating Factor (PAF) Antagonist and its Water-soluble Prodrug Phosphate Ester. J Med Chem 1992; 35:3474–3482PubMedGoogle Scholar
  86. Golik J, Wong HSL, Chen SH, Doyle TW, Wright JJ, Knipe J, Rose WC, Casazza AM, and Vyas DM. Synthesis and Antitumor Evaluation of Paclitaxel Phosphonooxymethyl Ethers: A Novel Class of Water Soluble Paclitaxel Prodrugs. Bioorg Med Chem Lett 1996; 6:1837–1842Google Scholar
  87. Gonzalez DE, Covitz KM, Sadee W, and Mrsny, RJ. An Oligopeptide Transporter is Expressed at High Levels in the Pancreatic Carcinoma Cell Lines AsPc-1 and Capan-2. Cancer Res 1998; 58:519–525PubMedGoogle Scholar
  88. Graul A, Leeson P, and Castaner J. Methylprednisolone Suleptanate. Corticosteroid Prodrug. Drugs of the Future 1997; 22:833–840Google Scholar
  89. Gunnarsson PO, Andersson SB, Johansson SA, Nilsson T, and Plym-Forshell G. Pharmacokinetics of Estramustine Phosphate (Estracyt) in Prostatic Cancer Patients. Eur J Clin Pharmacol 1984; 26:113–119PubMedGoogle Scholar
  90. Guo A, Hu P, Balimane PV, Leibach FH, and Sinko PJ. Interactions of a Nonpeptidic Drug, Valacyclovir, with the Human Intestinal Peptide Transporter (hPEPT1) Expressed in a Mammalian Cell Line. J Pharmacol Exp Therap 1999; 289:448–454Google Scholar
  91. Haba K, Popkov M, Shamis M, Lerner RA, Barbas CF III, and Shabat D. Single-triggered Trimeric Prodrugs. Angew Chem Int Ed 2005; 44:716–720Google Scholar
  92. Hammer K, Hatlelid J, Grotli M, Arukwe J, Klaveness J, Rise F, and Undheim K. Ether, Carbonate and Urethane Deoxynucleoside Derivatives as Prodrugs. Acta Chem Scand 1996; 50:609–622PubMedGoogle Scholar
  93. Han HK, Oh DM, and Amidon GL. Cellular Uptake Mechanism of Amino Acid Ester Prodrugs in Caco-2/hPEPT1 Cells Overexpressing a Human Peptide Transporter. Pharm Res 1998; 15:1382–1386PubMedGoogle Scholar
  94. Hande KR. Etoposide: Four Decades of Development of a Topoisomerase II Inhibitor. Eur J Cancer 1998; 34:1514–1521PubMedGoogle Scholar
  95. Hansen J, Mork N, and Bundgaard H. Phenyl Carbamates of Amino Acids as Prodrug Forms for Protecting Phenols against First-pass Metabolism. Int J Pharm 1992; 81:253–261Google Scholar
  96. Hansen KT, Faarup P, and Bundgaard H. Carbamate Ester Prodrugs of Dopaminergic Compounds: Synthesis, Stability, and Bioconversion. J Pharm Sci 1991; 80:793–798PubMedGoogle Scholar
  97. Hare LE, Yeh KC, Ditzler CA, McMahon FG, and Duggan DE. Bioavailability of Dexamethasone. II. Dexamethasone Phosphate. Clin Pharmacol Therap 1975; 18:330–337Google Scholar
  98. Hendler SS. Water-soluble Prodrugs of Propofol for Treatment of Migraine. US Patent # 2000-639015. 2002Google Scholar
  99. Hertzberg RP, Caranfa MJ, Holden KG, Jakas DR, Gallagher G, Mattern MR, Mong SM, Bartus JO, Johnson RK, and Kingsbury WD. Modification of the Hydroxy Lactone Ring of Camptothecin: Inhibition of Mammalian Topoisomerase I and Biological Activity. J Med Chem 1989; 32:715–20PubMedGoogle Scholar
  100. Hussain A, and Truelove JE. Prodrug Approaches to Enhancement of Physicochemical Properties of Drugs IV: Novel Epinephrine Prodrug. J Pharm Sci 1976; 65:1510–1512PubMedGoogle Scholar
  101. Ingelman-Sundberg M. Implications of Polymorphic Cytochrome P450-dependent Drug Metabolism for Drug Development. Drug Metab Dispos 2001; 29:570–573PubMedGoogle Scholar
  102. Irwin WJ, and Belaid KA. Drug-delivery by Ion-Exchange. Stability of Ester Prodrugs of Propranolol in Surfactant and Enzymatic Systems. Int J Pharm 1988; 48:159–166Google Scholar
  103. Jann MW, Ereshefsky L, and Saklad SR. Clinical Pharmacokinetics of the Depot Antipsychotics. Clin Pharmacokinet 1985; 10:315–333PubMedGoogle Scholar
  104. Jensen CB, and Jollow DJ. The Role of N-hydroxyphenetidine in Phenacetininduced Hemolytic Anemia. Toxicol Appl Pharmacol 1991; 111:1–12PubMedGoogle Scholar
  105. Jensen E, and Bundgaard H. Aminomethylbenzoate Esters of Chloramphenicol as a Novel Prodrug Type for Parenteral Administration. Int J Pharm 1991; 70:137–146Google Scholar
  106. Johansen M, and Bundgaard H. Prodrugs as Drug Delivery Systems. XVI. Novel Water-soluble Prodrug Types of Chlorzoxazone by Esterification of the Nhydroxymethyl Derivatives. Arch Pharm Chem Sci Edn 1981; 8:43–54Google Scholar
  107. Johansen M, and Larsen C. Stability and Kinetics of Hydrolysis of Metronidazole Monosuccinate in Aqueous Solution and in Plasma. Int J Pharm 1984; 21:201–209Google Scholar
  108. Johansen M, and Larsen C. A Comparison of the Chemical Stability and the Enzymic Hydrolysis of a Series of Aliphatic and Aromatic Ester Derivatives of Metronidazole. Int J Pharm 1985; 26:227–241Google Scholar
  109. Johnson K, Amidon GL, and Pogany S. Solution Kinetics of a Water-soluble Hydrocortisone Prodrug: Hydrocortisone-21-lysinate. J Pharm Sci 1985;74:87–89PubMedGoogle Scholar
  110. Jordan CG. How an Increase in the Carbon Chain Length of the Ester Moiety Affects the Stability of a Homologous Series of Oxprenolol Esters in the Presence of Biological Enzymes. J Pharm Sci 1998; 87:880–885PubMedGoogle Scholar
  111. Jung D, and Dorr A. Single-dose Pharmacokinetics of Valganciclovir in HIV-and CMV-seropositive Subjects. J Clin Pharmacol 1999; 39:800–804PubMedGoogle Scholar
  112. Kearney AS, and Stella VJ. The In Vitro Enzymic Labilities of Chemically Distinct Phosphomonoester Prodrugs. Pharm Res 1992; 9:497–503PubMedGoogle Scholar
  113. Kim I, Chu X-Y, Kim S, Provoda CJ, Lee K-Y, and Amidon GL. Identification of a Human Valacyclovirase. J Biol Chem 2003; 278:25348–25356PubMedGoogle Scholar
  114. Klixbull U, and Bundgaard H. Prodrugs as Drug Delivery Systems. XXIX. Imidazole-1-carboxylic Acid Esters of Hydrocortisone and Testosterone. Archiv for Pharmaci og Chem Sci Ed 1983; 11:1065–1074Google Scholar
  115. Kovach IM, Pitman IH, and Higuchi T. Amino Acid Esters of Phenols as Prodrugs: Synthesis and Stability of Glycine, beta-Aspartic Acid, and alpha-Aspartic Acid Esters of p-Acetamidophenol. J Pharm Sci 1981; 70:881–885PubMedGoogle Scholar
  116. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, and Mutai M. Antitumor Activity of 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, A Novel Water-soluble Derivative of Camptothecin, against Murine Tumors. Cancer Res 1987;47:5944–5947PubMedGoogle Scholar
  117. Landowski C, Vig B, Song X, and Amidon, G. Targeted Delivery to PEPT1-Overexpressing Cells: Acidic, Basic, and Secondary Floxuridine Amino Acid Ester Prodrugs. Mol Cancer Therap 2005; 4:659–667Google Scholar
  118. Larsen C, Kurtzhals P, and Johansen M. Kinetics of Regeneration of Metronidazole from Hemiesters of Maleic Acid, Succinic Acid and Glutaric Acid in Aqueous Buffer, Human Plasma and Pig Liver Homogenate. Int J Pharm 1988; 41:121–129Google Scholar
  119. Leinweber FJ. Possible Physiological Roles of Carboxylic Ester Hydrolyases. Drug Metab Rev 1987; 18:379–439PubMedGoogle Scholar
  120. Lin AJ, Cosby LA, Shansky CW, and Sartorelli AC. Potential Bioreductive Alkylating Agents. 1. Benzoquinone Derivatives. J Med Chem 1972;15:1247–1252PubMedGoogle Scholar
  121. Lipinski CA, Lombardo F, Dominy BW, and Feeney PJ. Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings. Adv Drug Deliv Rev 1997; 23:3–25Google Scholar
  122. List B, Shabat D, Zhong G, Turner JM, Li A, Bui T, Anderson J, Lerner RA, and Barbas CF III. A Catalytic Enantioselective Route to Hydroxy-substituted Quaternary Carbon Centre: Resolution of Tertiary Aldols with a Catalytic Antibody. J Am Chem Soc 2000; 121:7283–7291Google Scholar
  123. Lobo RA, and Cassident DL. Pharmacokinetics of Oral 17b-Estradiol. J Reprod Med 1992; 37:77–84PubMedGoogle Scholar
  124. Lokind KB, Lorenzen FH, and Bundgaard H. Oral Bioavailability of 17b-Estradiol and Various Ester Prodrugs in the Rat. Int J Pharm 1991; 76:177–182Google Scholar
  125. Lombardino JG, and Wiseman EH. Sudoxicam and Related N-heterocyclic Carboxamides of 4-Hydroxy-2H-1,2-benzothiazine 1,1-dioxide. Potent Nonsteroidal Antiinflammatory Agents. J Med Chem 1972; 15:848–849PubMedGoogle Scholar
  126. Longcope C, Gorbach S, Goldin B, Woods M, Dwyer J, and Warram J. The Metabolism of Estradiol; Oral Compared to Intravenous Administration. J Steroid Biochem 1985; 23:1065–1070PubMedGoogle Scholar
  127. Loo JC, McGilveray IJ, Jordan N, and Brien R. Pharmacokinetic Evaluation of Betamethasone and its Water Soluble Phosphate Ester in Humans. Biopharm Drug Dispos 1981; 2:265–272PubMedGoogle Scholar
  128. Lougerstay-Madec R, Florent J-C, Monneret C, Nemati F, and Poupon MF. Synthesis of Self-immolative Glucuronide-based Prodrugs of a Phenol Mustard. Anti-Cancer Drug Design 1998; 13:995–1007PubMedGoogle Scholar
  129. Luber AD, and Flaherty JF. Famciclovir for Treatment of Herpesvirus Infections. Ann Pharmacother 1996; 30:978–985PubMedGoogle Scholar
  130. Mahfouz NM, and Hassan MA. Synthesis, Chemical and Enzymatic Hydrolysis, and Bioavailability Evaluation in Rabbits of Metronidazole Amino Acid Ester Prodrugs with Enhanced Water Solubility. J Pharm Pharmacol 2001; 53:841–848PubMedGoogle Scholar
  131. Mantyla A, Garnier T, Rautio J, Nevalainen T, Vepsalainen J, Koskinen A, Croft Simon L, and Jarvinen T. Synthesis, In Vitro Evaluation, and Antileishmanial Activity of Water-soluble Prodrugs of Buparvaquone. J Med Chem 2004;47:188–195PubMedGoogle Scholar
  132. Martin DF, Sierra-Madero J, Walmsley S, Wolitz RA, Macey K, Georgiou P, Robinson CA, and Stempien MJ. A Controlled Trial of Valganciclovir as Induction Therapy for Cytomegalovirus Retinitis. N Engl J Med 2002;346:1119–1126PubMedGoogle Scholar
  133. Mathew AE, Mejillano MR, Nath JP, Himes RH, and Stella VJ. Synthesis and Evaluation of Some Water-soluble Prodrugs and Derivatives of Taxol with Antitumor Activity. J Med Chem 1992; 35:145–151PubMedGoogle Scholar
  134. Melby JC, and St. Cyr M. Comparative Studies on Absorption and Metabolic Disposal of Water-soluble Corticosteroid Esters. Metab Clin Exp 1961; 10:75–82PubMedGoogle Scholar
  135. Milstien S, and Cohen LA. Stereopopulation Control. I. Rate Enhancement in the Lactonizations of o-Hydroxyhydrocinnamic Acids. J Am Chem Soc 1972;94:9158–9165PubMedGoogle Scholar
  136. Mollmann H, Rohdewald P, Schmidt EW, Salomon V, and Derendorf H. Pharmacokinetics of Triamcinolone Acetonide and its Phosphate Ester. Eur J Clin Pharmacol 1985; 29:85–89PubMedGoogle Scholar
  137. Morimoto BH, and Barker PL. Preparation of Phosphocholine Linked Prodrug Derivatives. US Patent # 99-120483. (Feb 18th). 1999Google Scholar
  138. Mummaneni V, Kaul S, Igwemezie LN, Newell DR, Porter D, Thomas H, Calvert AH, Winograd B, and Barbhaiya RH. Bioequivalence Assessment of Etoposide Phosphate and Etoposide Using Pharmacodynamic and Traditional Pharmacokinetic Parameters. J Pharmacokinet Biopharm 1996; 24:313–325PubMedGoogle Scholar
  139. Nahata MC, and Powell DA. Bioavailability and Clearance of Chloramphenicol after Chloramphenicol Succinate. Clin Pharmacol Therap 1981; 30:368–372Google Scholar
  140. Nakane M, and Iwama H. A Potential Mechanism of Propofol-induced Pain on Injection Based on Studies using Nafamostat Mesilate. Br J Anaesth 1999;83:397–404PubMedGoogle Scholar
  141. Nakanishi T, Tamai I, Takaki A, and Tsuji A. Cancer Cell-targeted Drug Delivery Utilizing Oligopeptide Transport Activity. Int J Cancer 2000; 88:274–280PubMedGoogle Scholar
  142. Naylor MA, and Thomson P. Recent Advances in Bioreductive Drug Targeting. Mini-Rev Med Chem 2001; 1:17–29PubMedGoogle Scholar
  143. Novak E, Wagner JG, and Lamb DJ. Local and Systemic Tolerance, Absorption and Excretion of Clindamycin Hydrochloride after Intramuscular Administration. Int J Clin Pharmacol Ther Toxicol 1970; 3:201–208Google Scholar
  144. Olsson O, and Svensson LA. New Lipophilic Terbutalin Ester Prodrugs with Long Effect Duration. Pharm Res 1984; 1:19–23Google Scholar
  145. Padilla De Jesús OL, Ihre HR, Gagne L, Fréchet JMJ, and Szoka FC. Polyester Dendritic Systems for Drug Delivery Applications: In Vitro and In Vivo Evaluation. Bioconjugate Chem 2002; 13:453–461Google Scholar
  146. Pessah N, Reznik M, Shamis M, Yantiri F, Xin H, Bowdish K, Shomron N, Ast G, and Shabat D. Bioactivation of Carbamate-based 20(S)-camptothecin Prodrugs. Bioorg Med Chem 2004; 12:1859–1866PubMedGoogle Scholar
  147. Pettit GR, and Lippert JW 3rd. Antineoplastic agents 429. Syntheses of the Combretastatin A-1 and Combretastatin B-1 Prodrugs. Anticancer Drug Des 2000;15:203–216PubMedGoogle Scholar
  148. Pop E, Soti F, Brewster ME, Barenholz Y, Korablyov V, Mechoulam R, Nadler V, and Biegon A. Derivatives of Dexanabinol. II. Salts of Amino Acid Esters Containing Tertiary and Quaternary Heterocyclic Nitrogen with Increased Water-solubility. Pharm Res 1996; 13:469–475PubMedGoogle Scholar
  149. Pop E, Rachwal S, Vlasak J, Biegon A, Zharikova A, and Prokai L. In Vitro and In Vivo Study of Water-soluble Prodrugs of Dexanabinol. J Pharm Sci 1999; 88:1156–1160PubMedGoogle Scholar
  150. Rattie ES, Shami EG, Dittert LW, and Swintosky JV. Acetaminophen Prodrugs. 3. Hydrolysis of Carbonate and Carboxylic Acid Esters in Aqueous Buffers. J Pharm Sci 1970; 59:1738–1741PubMedGoogle Scholar
  151. Reusser P. Oral Valganciclovir: A New Option for Treatment of Cytomegalovirus Infection and Disease in Immunocompromised Hosts. Expert Opin Invest Drugs 2001; 10:1745–1753Google Scholar
  152. Richardson K, Cooper K, Marriot MS, Tarbit MH, Troke PF, and Whittle PJ. Discovery of Fluconazole, A Novel Antifungal Agent. Rev Infect Disease 1990; 12:S267–S271Google Scholar
  153. Riebe KW, and Oesterling TO. Parenteral Development of Clindamycin-2-phosphate. Bull Parenteral Drug Assoc 1972; 26:139–146Google Scholar
  154. Roberts AP, Eastwood JB, Gower PE, Fenton CM, and Curtis JR. Serum and Plasma Concentrations of Clindamycin Following a Single Intramuscular Injection of Clindamycin Phosphate in Maintenance Hemodialysis Patients and Normal Subjects. Eur J Clin Pharmacol 1978; 14:435–439PubMedGoogle Scholar
  155. Robinson RP, Reiter LA, Barth WE, Campeta AM, Cooper K, Cronin BJ, Destito R, Donahue KM, Falkner FC, Fiese E, Johnson D, Kuperman A, Liston T, Malloy D, Martin J, Mitchell D, Rusek F, Shamblin S, and Wright C. Discovery of the Hemifumarate and (α-L-alanyloxy)methyl Ether as Prodrugs of an Antirheumatic Oxindole: Prodrugs for the Enolic OH Group. J Med Chem 1996; 39:10–18PubMedGoogle Scholar
  156. Rodrigues ML, Carter P, Wirth C, Mullins S, Lee A, and Blackburn BK. Synthesis and beta-Lactamase-mediated Activation of a Cephalosporin-Taxol Prodrug. Chem Biol 1995; 2:223–227PubMedGoogle Scholar
  157. Rodriguez MJ, Vasudevan V, Jamison JA, Borromeo PS, and Turner WW. The Synthesis of Water Soluble Prodrugs Analogs of Echinocandin B. Bioorg Med Chem Lett 1999; 9:1863–1868PubMedGoogle Scholar
  158. Ross D, Beall H, Siegel D, Traver RD, and Gustafson DL. Enzymology of Bioreduction Drug Activation. Br J Can Suppl 1996; 27:S1–S8Google Scholar
  159. Rubio-Aliaga I, and Daniel H. Mammalian Peptide Transporters as Targets for Drug Delivery. Trends Pharmacol Sci 2002; 23:434–440PubMedGoogle Scholar
  160. Saari WS, Schwering JE, Lyle PA, Smith SJ, and Engelhardt EL. Cyclizationactivated Prodrugs. Basic Carbamates of 4-Hydroxyanisole. J Med Chem 1990a; 33:97–101PubMedGoogle Scholar
  161. Saari WS, Schwering JE, Lyle PA, Smith SJ, and Engelhardt EL. Cyclizationactivated Prodrugs. Basic Esters of 5-Bromo-2′-deoxyuridine. J Med Chem 1990b; 33:2590–2595PubMedGoogle Scholar
  162. Sadler BM, Hanson CD, Chittick GE, Symonds WT, and Roskell NS. Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor, Following Oral Administration of Single Doses to HIV-infected Adults. Antimicrob Agents Chemother 1999; 43:1686–1692PubMedGoogle Scholar
  163. Safadi M, Oliyai R, and Stella VJ. Phosphoryloxymethyl Carbamates and Carbonates-Novel Water-soluble Prodrugs for Amines and Hindered Alcohols. Pharm Res 1993; 10:1350–1355PubMedGoogle Scholar
  164. Sagara Y, Hendler S, Khoh-Reiter S, Gillenwater G, Carlo D, Schubert D, and Chang J. Propofol Hemisuccinate Protects Neuronal Cells from Oxidative Injury. J Neurochem 1999; 73:2524–2530PubMedGoogle Scholar
  165. Saulnier MG, Langley DR, Kadow JF, Senter PD, Knipe JO, Tun MM, Vyas DM, and Doyle TW. Synthesis of Etoposide Phosphate, BMY-40481: A Water-soluble Clinically Active Prodrug of Etoposide. Bioorg Med Chem Lett 1994; 4:2567–2572Google Scholar
  166. Schmidt F, and Monneret C. Prodrug Mono Therapy: Synthesis and Biological Evaluation of an Etoposide Glucuronide-Prodrug. Bioorg Med Chem 2003; 11:2277–2283PubMedGoogle Scholar
  167. Schmidt F, Ungureanu I, Duval R, Pompon A, and Monneret C. Cancer Chemotherapy: A Paclitaxel Prodrug for ADEPT (Antibody-Directed Enzyme Prodrug Therapy). Eur J Org Chem 2001; 2129–2134Google Scholar
  168. Senter PD, Saulnier MG, Schreiber GJ, Hirschberg DL, Brown JP, Hellstrom I, and Hellstrom KE. Anti-tumor Effects of Antibody-Alkaline Phosphatase Conjugates in Combination with Etoposide Phosphate. Proc Natl Acad Sci 1988; 85:4842–4846PubMedGoogle Scholar
  169. Sessa C, Zucchetti M, Cerny T, Pagani O, Cavalli F, De Fusco M, De Jong J, Gentili D, McDaniel C, and Prins C. Phase I Clinical and Pharmacokinetic Study of Oral Etoposide Phosphate. J Clin Oncol 1995; 13:200–209PubMedGoogle Scholar
  170. Shabat D, Rader C, List B, Lerner RA, and Barbas CF 3rd. Multiple Event Activation of a Generic Prodrug Trigger by Antibody Catalysis. Proc Natl Acad Sci 1999; 96:6925–6930PubMedGoogle Scholar
  171. Shabat D, Lode HN, Pertl U, Reisfeld RA, Rader C, Lerner RA, and Barbas CF 3rd. In Vivo Activity in a Catalytic Antibody-Prodrug System: Antibody Catalyzed Etoposide Prodrug Activation for Selective Chemotherapy. Proc Natl Acad Sci 2001; 98:7528–7533PubMedGoogle Scholar
  172. Shah JC, Chen JR, and Chow D. Preformulation Study of Etoposide: Identification of Physicochemical Characteristics Responsible for the Low and Erratic Oral Bioavailability of Etoposide. Pharm Res 1989; 6:408–412PubMedGoogle Scholar
  173. Shamis M, Lode HN, and Shabat D. Bioactivation of Self-immolative Dendritic Prodrugs by Catalytic Antibody 38C2. J Am Chem Soc 2004; 126:1726–1731PubMedGoogle Scholar
  174. Sinkula AA, and Yalkowsky SH. Rationale for Design of Biologically Reversible Drug Derivatives: Prodrugs. J Pharm Sci 1975; 64:181–210PubMedGoogle Scholar
  175. Sitar DS. Clinical Pharmacokinetics of Bambuterol. Clinical Pharmacokin 1996; 31:246–256Google Scholar
  176. Slatter JG, Schaaf LJ, Sams JP, Feenstra KL, Johnson MG, Bombardt PA, Cathcart KS, Verburg MT, Pearson LK, Compton LD, Miller LL, Baker DS, Pesheck CV, Lord RS 3rd. Pharmacokinetics, Metabolism, and Excretion of Irinotecan (CPT-11) following I.V. Infusion of [(14)C]CPT-11 in Cancer Patients. Drug Metab Dispos 2000; 28:423–433PubMedGoogle Scholar
  177. Slatter JG, Su P, Sams JP, Schaaf LJ, and Wienkers LC. Bioactivation of the Anticancer Agent CPT-11 to SN-38 by Human Hepatic Microsomal Carboxylesterases and the In Vitro Assessment of Potential Drug Interactions. Drug Metab Dispos 1997; 25:1157–1164PubMedGoogle Scholar
  178. Sobue S, Tan K, Layton G, Eve M, and Sanderson JB. Pharmacokinetics of Fosfluconazole and Fluconazole following Multiple Intravenous Administration of Fosfluconazole in Healthy Male Volunteers. Br J Clin Pharmacol 2004; 58:20–25PubMedGoogle Scholar
  179. Sobue S, Tan K, and Haug-Pihale G. The Effects of Hepatic Impairment on the Pharmacokinetics of Fosfluconazole and Fluconazole following a Single Intravenous Bolus Injection of Fosfluconazole. Br J Clin Pharmacol 2005; 59:160–166PubMedGoogle Scholar
  180. Sonne J, Loft S, Doessing M, Vollmer-Larsen A, Olesen KL, Victor M, Andreasen F, and Andreasen PB. Bioavailability and Pharmacokinetics of Oxazepam. Eur J Clin Pharmacol 1988; 35:385–389PubMedGoogle Scholar
  181. Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, and Posner J. Absolute Bioavailability and Metabolic Disposition of Valaciclovir, the L-valyl Ester of Acyclovir, following Oral Administration to Humans. Antimicrob Agents Chemother 1995; 39:2759–2764PubMedGoogle Scholar
  182. Sparreboom A, de Jonge MJ, de Bruijn P, Brouwer E, Nooter K, Loos WJ, van Alphen RJ, Mathijssen RH, Stoter G, and Verweij J. Irinotecan (CPT-11) Metabolism and Disposition in Cancer Patients. Clin Cancer Res 1998; 4:2747–2754PubMedGoogle Scholar
  183. Springer CJ, and Niculescu-Duvaz I. Prodrug-activating Systems in Suicide Gene Therapy. J Clin Invest 2000; 105:1161–1167PubMedGoogle Scholar
  184. Springer CJ, Dowell R, Burke PJ, Hadley E, Davies DH, Blakey DC, Melton RG, and Niculescu-Duvaz I. Optimization of Alkylating Agent Prodrugs Derived from Phenol and Aniline Mustards: A New Clinical Candidate Prodrug (ZD2767) for Antibody-Directed Enzyme Prodrug Therapy. J Med Chem 1995; 38:5051–5065PubMedGoogle Scholar
  185. Stella VJ. A Case for Prodrugs: Fosphenytoin. Adv Drug Delivery Rev 1996; 19:311–330Google Scholar
  186. Stella VJ, Zygmunt JJ, Georg GI, and Safadi MS. Water-soluble Prodrugs of Hindered Alcohols or Phenols. US Patent # 98-131385. (Aug 07). 2000Google Scholar
  187. Sugar AM, and Liu XP. In Vitro and In Vivo Activities of SCH 56592 against Blastomyces Dermatitidis. Antimicrob Agents Chemother 1996; 40:1314–1316PubMedGoogle Scholar
  188. Sugawara M, Huang W, Fei Y-J, Leibach FH, Ganapathy V, and Ganapathy ME. Transport of Valganciclovir, a Ganciclovir Prodrug, via Peptide Transporters PEPT1 and PEPT2. J Pharm Sci 2000; 89:781–789PubMedGoogle Scholar
  189. Svensson LA, and Tunek A. The Design and Bioactivation of Presystematically Stable Prodrugs. Drug Metab Rev 1988; 19:165–194PubMedGoogle Scholar
  190. Takahashi K, Haginaka J, Tamagawa S, Nishihata T, Yasuda H, and Katagi T. Stereoselective Hydrolysis of O-Acetyl Propranolol as Prodrug in Human Serum. J Pharm Pharmacol 1990; 42:356–357PubMedGoogle Scholar
  191. Takahashi K, Tamagawa S, Haginaka J, Yasuda H, Katagi T, and Mizuno N. Stereoselective Hydrolysis of O-Acetyl Propranolol as Prodrug in Rat Tissue Homogenates. J Pharm Sci 1992; 81:226–227PubMedGoogle Scholar
  192. Tan CH, and Onsiong MK. Pain on Injection of Propofol. Anaesthesia 1998; 53:468–476PubMedGoogle Scholar
  193. Tannock IF, and Rotin D. Acid pH in Tumors and Its Potential for Therapeutic Exploitation. Cancer Res 1989; 49:4373–4384PubMedGoogle Scholar
  194. TenHoor CN, and Stewart BH. Reconversion of Fosphenytoin in the Presence of Intestinal Alkaline Phosphatase. Pharm Res 1995; 12:1806–1809PubMedGoogle Scholar
  195. Thomsen KF, and Bundgaard H. Cyclization-activated Phenyl Carbamate Prodrug Forms for Protecting Phenols against First-pass Metabolism. Int J Pharm 1993; 91:39–49Google Scholar
  196. Thomsen, KF, Strom F, Sforzini BV, Begtrup M, and Mork N. Evaluation of Phenyl Carbamates of Ethyl Diamines as Cyclization-activated Prodrug Forms for Protecting Phenols against First-pass Metabolism. Int J Pharm 1994; 112:143–152Google Scholar
  197. Tietze LF, and Feuerstein T. Review: Highly Selective Compounds for the Antibody-directed Enzyme Prodrug Therapy of Cancer. Aust J Chem 2003; 56:841–854Google Scholar
  198. Toki BE, Cerveny CG, Wahl AF, and Senter PD. Protease-mediated Fragmentation of p-Amidobenzyl Ethers: A New Strategy for the Activation of Anticancer Prodrugs. J Org Chem 2002; 67:1866–1872PubMedGoogle Scholar
  199. Troke PF. Large-scale Multicentre Study of Fluconazole in the Treatment of Hospitalised Patients with Fungal Infections. Multicentre European Study Group. Eur J Clin Microbiol Infect Dis 1997; 16:287–295PubMedGoogle Scholar
  200. Tsuji A, and Tamai I. Carrier-mediated Intestinal Transport of Drugs. Pharm Res 1996; 13:963–977PubMedGoogle Scholar
  201. Tsuzuki N, Hama T, Kawada M, Hasui R, Konishi S, Shiwa Y, Ochi Y, Futaki S, and Kitagawa K. Adamantane as a Brain-directed Drug Carrier for Poorly Absorbed Drug 2. AZT Derivatives Conjugated with the 1-Adamantane Moiety. J Pharm Sci 1994; 83:481–484PubMedGoogle Scholar
  202. Tunek A, Levin E, and Svensson LA. Hydrolysis of 3H-Bambuterol, A Carbamate Prodrug of Terbutaline, in Blood from Humans and Laboratory Animals In Vitro. Biochem Pharmacol 1988; 37:3867–3876PubMedGoogle Scholar
  203. Ueda Y, Mikkilineni AB, Knipe JO, Rose WC, Casazza AM, and Vyas DM. Novel Water Soluble Phosphate Prodrugs of Taxol Possessing In Vivo Antitumor Activity. Bioorg Med Chem Lett 1993; 3:1761–1766Google Scholar
  204. Varia SA, Schuller, S, Sloan KB, and Stella VJ. Phenytoin Prodrugs III: Watersoluble Prodrugs for Oral and/or Parenteral Use. J Pharm Sci 1984; 73:1068–1073PubMedGoogle Scholar
  205. Vermeersch H, Remon JP, Permentier D, and Schacht E. In Vitro Antitrichomonal Activity of Water-soluble Prodrug Esters of Metronidazole. Int J Pharm 1990; 253–260Google Scholar
  206. Veronese L, Rautaureau J, Sadler BM, Gillotin C, Petite JP, Pillegand B, Delvaux M, Masliah C, Fosse S, Lou Y, and Stein DS. Single-dose Pharmacokinetics of Amprenavir, A Human Immunodeficiency Virus Type 1 Protease Inhibitor, in Subjects with Normal or Impaired Hepatic Function. Antimicrob Agents Chemother 2000; 44:821–826PubMedGoogle Scholar
  207. Veronese ME, McLean S, D’Souza CA, and Davies NW. Formation of Reactive Metabolites of Phenacetin in Humans and Rats. Xenobiotica 1985; 15:929–940PubMedGoogle Scholar
  208. Vrudhula VM, Kerr DE, Siemers NO, Dubowchik GM, Senter PD. Cephalosporin Prodrugs of Paclitaxel for Immunologically Specific Activation by L-49-sFv-beta-Lactamase Fusion Protein. Bioorg Med Chem Lett 2003; 13:539–542PubMedGoogle Scholar
  209. Vyas DM, Wong H, Crosswell AR, Casazza AM, Knipe J, Mamber SW, and Doyle TW. Synthesis and Antitumor Evaluation of Water Soluble Taxol Phosphates. Bioorg Med Chem Lett 1993; 3:1357–1360Google Scholar
  210. Wakselman, M. The 1,4 and 1,6 Eliminations from Hydroxy-and Aminosubstituted Benzyl Systems: Chemical and Biochemical Applications. Nouv J Chim 1983; 7:439–447Google Scholar
  211. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, and Sim GA. Plant Antitumor Agents. I. Isolation and Structure of Camtothecin, A Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca Acuminata. J Am Chem Soc 1966; 88:3888–3890Google Scholar
  212. Wang B, Gangwar S, Pauletti GM, Siahaan, TJ, and Borchardt RT. Synthesis of a Novel Esterase-Sensitive Cyclic Prodrug System for Peptides That Utilizes a “Trimethyl Lock”-Facilitated Lactonization Reaction. J Org Chem 1997; 62:1363–1367Google Scholar
  213. Wani MC, Nicholas AW, and Wall ME. Plant Antitumor Agents. 23. Synthesis and Antileukemic Activity of Camptothecin Analogues. J Med Chem 1986; 29:2358–2363PubMedGoogle Scholar
  214. Wei CP, Anderson JA, and Leopold I. Ocular Absorption and Metabolism of Topically Applied Epinephrine and a Dipivalyl Ester of Epinephrine. Invest Ophthalmol Vis Sci 1978; 17:315–321PubMedGoogle Scholar
  215. Williams FM. Clinical Significance of Esterases in Man. Clin Pharmacokinet 1985; 10:392–403PubMedGoogle Scholar
  216. Winkelmann E, Winkler I, Rolly H, Rosner M, and Jahne G. New Prodrugs of Acyclic Nucleosides with Antiviral Activity. Arzneim Forsch 1988; 38:1545–1548Google Scholar
  217. Winum J-Y, Scozzafava A., Montero J-L, and Supuran CT. Sulfamates and their Therapeutic Potential. Med Res Rev 2005; 25:186–228PubMedGoogle Scholar
  218. Wood R, Arasteh K, Stellbrink HJ, Teofilo E, Raffi F, Pollard RB, Eron J, Yeo J, Millard J, Wire MB, and Naderer OJ. Six-week Randomized Controlled Trial to Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients. Antimicrob Agents Chemother 2004; 48:116–123PubMedGoogle Scholar
  219. Yagi S, Ono J, Yoshimoto J, Sugita K-I, Hattori N, Fujioka T, Fujiwara T, Sugimoto H, Hirano K, and Hashimoto N. Development of Anti-influenza Virus Drugs I: Improvement of Oral Absorption and In Vivo Anti-Influenza Activity of Stachyflin and Its Derivatives. Pharm Res 1999; 16:1041–1046PubMedGoogle Scholar
  220. Yoshimura H, Watanabe K, Oguri K, Fujiwara M, and Ueki S. Synthesis and Pharmacological Activity of a Phosphate Ester of Delta 8-Tetrahydrocannabinol. J Med Chem 1978; 21:1079–1081PubMedGoogle Scholar
  221. Zhang Z, Tanabe K, Hatta H, and Nishimoto S. Bioreduction Activated Prodrugs of Camptothecin: Molecular Design, Synthesis, Activation Mechanism and Hypoxia Selective Cytotoxicity. Org Biomol Chem 2005; 3:1905–1910.PubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2007

Authors and Affiliations

  • Sundeep S. Dhareshwar
    • 1
  • Valentino J. Stella
    • 1
  1. 1.Department of Pharmaceutical ChemistryThe University of KansasLawrenceUSA

Personalised recommendations